ClinicalTrials.gg
RecruitingNCT06795035ConMICROUpdated Oct 1, 2026

Assessment of Coronary Microvascular Dysfunction After STEMI Using Continuous Saline Thermodilution

An observational study in ST Elevation Myocardial Infarction, Coronary Microvascular Dysfunction and Microvascular Obstruction, sponsored by The Cleveland Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by The Cleveland Clinic · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.
Updated Oct 1, 2026Enrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
35
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 83 studies in ST Elevation Myocardial Infarction with a site in United States — 6 open to participants now, 11 under way, 1 of them phase 3. ST Elevation Myocardial Infarction · United States.

Planned enrollment
24th of 27
35 · median 324
Started
2025
with 3 others
Observational
27 of 83
3 open now
Primary completion
2027-12
later than 8 of 10 live
Registered
80th of 83
by date

Among the 83 studies in ST Elevation Myocardial Infarction with a site in United States, this one is the 24th largest by planned enrollment of the 27 observational ones that give a count, is one of 4 that started in 2025, is one of 27 observational ones, reaches primary completion later than 8 of the 10 other live ones, and was the 80th registered.

ST Elevation Myocardial Infarction

855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.

Browse ST Elevation Myocardial Infarction studies →

Open to participants now

6 of the 83 studies in ST Elevation Myocardial Infarction with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in ST Elevation Myocardial Infarction with a site in United States, or all of them as a file.
02

Study summary

The goal of this observational study to measure the heart's microvascular function in the setting of a myocardial infarction (MI), or heart attack, using a method called continuous saline thermodilution (CST). The participants will include people who are experiencing MI from sudden and complete blockage of a coronary artery requiring immediate balloon and/or stent therapy. After getting the balloon and/or stent therapy, participants will have their heart's microvascular system tested using CST. The main questions it aims to answer are:

  • What measurements using CST can we expect from the heart's microvascular system during a treated MI?
  • Can CST measurements during a treated MI predict the amount of heart muscle that is injured and that recovers?

For this study, participants will undergo measurement of their heart's microvascular function after balloon and/or stent therapy for the MI. They will then receive an MRI scan of the heart several days after the MI.

Read the detailed description

This will be a non-interventional, prospective, descriptive analysis on a cohort of patients experiencing ST-elevation myocardial infarction (STEMI) who present to the Cleveland Clinic cardiac catheterization laboratory (CCL) for emergent primary percutaneous coronary intervention (PCI). The aim is to study acute coronary microvascular dysfunction using the method of continuous saline thermodilution to provide absolute measurements of coronary blood flow, coronary microvascular resistance, and microvascular resistance reserve (MRR) following primary PCI for STEMI patients.

Adult patients experiencing acute STEMI who present to the catheterization laboratory for emergent cardiac catheterization for STEMI, \<24 hours after symptom onset, who undergo primary PCI to an IRA. Only those able to provide initial oral consent upon CCL presentation and confirmatory written consent following cardiac catheterization will be included in the study.

Study endpoints are part of usual standard practice, and include clinic visits with updated medical histories and physical examination, and echocardiography. Clinical endpoints of interest will include mortality, incident heart failure, anginal symptoms, and standard major adverse cardiac events including cardiac death, nonfatal MI, urgent coronary revascularization, or hospitalization for unstable angina.

03

Conditions studied

  • ST Elevation Myocardial Infarction
  • Coronary Microvascular Dysfunction
  • Microvascular Obstruction

Keywords

  • STEMI
  • Microvascular
  • MVO
  • MRR
  • Thermodilution
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults presenting to catheterization lab within 24 hours of ischemic symptom onset with intent for emergent primary PCI due to STEMI on ECG or who have failed thrombolytic therapy and present for pharmaco-invasive management of STEMI.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (persons >18 years old) presenting to Cleveland Clinic cardiac catheterization lab within 24 hours of symptom onset, with clinical and findings concerning for STEMI, with intent to undergo emergent primary PCI, who have culprit artery identified on diagnostic angiography
  • Adults (persons >18 years old) presenting to Cleveland Clinic cardiac catheterization lab for pharmaco-invasive management of failed fibrinolysis, with intent to undergo emergent PCI, who have culprit artery identified on diagnostic angiography
  • On-call treating interventional cardiologist is trained in the method of continuous saline thermodilution for coronary microvascular assessment

Exclusion criteria

Exclusion Criteria:

  • No evidence of coronary obstruction on diagnostic angiography (e.g., Takotsubo, myocarditis leading to STEMI activation).
  • Patients in hemodynamic shock
  • Culprit artery \<3.0 mm in diameter.
  • Culprit artery being a bypass graft
  • Patients physically unable to tolerate additional time required to conduct coronary microvascular testing after primary PCI.
  • Patients with \<30 mL/min/1.73m2 are excluded from contributing cardiac MRI data
  • Patients with standard to CMR (e.g., pacemakers, cochlear implants, certain prosthetic heart valves, certain surgical implants) are excluded from contributing cardiac MRI data
  • Unable to provide verbal and written consent
  • Pregnancy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
35 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testContinuous Saline Thermodilution

    Continuous saline thermodilution for determination of microvascular resistance reserve (MRR) is a novel operator-independent method to assess coronary microvascular function. CST has been studied in the setting of angina with nonobstructive coronary arteries (ANOCA), but not in the setting of acute MI. In contrast, bolus thermodilution, used to determine the index of microcirculatory resistance (IMR), has been shown in the setting of STEMI to predict extent of myocardial injury and long-term clinical outcomes (e.g., heart failure, mortality, nonfatal MI, and ischemic stroke). In contrast to bolus thermodilution techniques, CST does not require the use of active medications (e.g., papaverine or adenosine) -- only a small volume of normal saline.

06

What researchers measure

Primary outcomes

  1. Microvascular resistance reserve (MRR)

    Calculated index to assess coronary microvascular dysfunction (Q\_hyperemia/Q\_rest)\*(Pa\_rest/Pd\_hyperemia)

    Time frame: At enrollment

Secondary outcomes

  1. Change in LV Wall Motion Summed Score

    Global wall motion abnormality score by echo based on 16 segment model (0= normal, 1=mild hypokinetic, 2= hypokinetic, 3= severely hypokinetic, 4= akinetic, 5= aneurysmal)

    Time frame: From 1-day echo to 3-month routine follow up echo

  2. Change in LVEF

    Left ventricular ejection fraction as quantified by routine baseline echo to routine follow up echo

    Time frame: From 1-day echo to 3-month routine follow up echo

  3. Presence of microvascular obstruction

    Presence of microvascular obstruction on cardiac MRI

    Time frame: Within 3 days of hospital discharge

07

Study locations

1 of 1 sites recruiting
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
    Recruiting
    • Vincent Chen, MD · ContactCHENV3@ccf.org · 440-226-1994
    • Khaled Ziada, MD · Principal investigator
    • Vincent Chen, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2027, 31 months after the start.

Of 122 non-industry observational studies under ST Elevation Myocardial Infarction, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 107. This study's planned 31 months is below that.

Counting every sponsor, half of 143 studies reached it within 38 months; a quarter within 21 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2025
First posted
Jan 27, 2025
StartActual
May 29, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
70→35
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Enrollment 70→35
    + 3 other changes: identifiers, verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06795035
Collaborators
Abbott
Responsible party
Khaled Ziada, MD (Interventional Cardiologist, The Cleveland Clinic) — Principal investigator
First posted
Jan 27, 2025
Start date
May 29, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 1, 2026

Study contacts

Khaled Ziada, MD
Contact
ziadak@CCF.ORG
216-444-0926
Vincent Chen, MD
Contact
chenv3@ccf.org
440-226-1994
Khaled Ziada, MD
principal investigator · The Cleveland Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion